Objective-Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is a predictor for incident atherosclerotic disease. We investigated the effect of 3 hypolipidemic drugs that exert their action through different mechanisms on plasma and lipoprotein-associated Lp-PLA 2 activity and mass. Methods and Results-In 50 patients with Type IIA dyslipidemia were administered rosuvastatin (10 mg daily), whereas in 50 Type IIA dyslipidemic patients exhibiting intolerance to previous statin therapy were administered ezetimibe as monotherapy (10 mg daily). Fifty patients with Type IV dyslipidemia were given micronised fenofibrate (200 mg daily). Low-and high-density lipoprotein (LDL and HDL, respectively) subclass analysis was performed electrophoretically, whereas lipoprotein subfractions were isolated by ultracentrifugation. Ezetimibe reduced plasma Lp-PLA 2 activity and mass attributable to the reduction in plasma levels of all LDL subfractions. Rosuvastatin reduced enzyme activity and mass because of the decrease in plasma levels of all LDL subfractions and especially the Lp-PLA 2 on dense LDL subfraction (LDL-5). Fenofibrate preferentially reduced the Lp-PLA 2 activity and mass associated with the VLDLϩIDL and LDL-5 subfractions. Among studied drugs only fenofibrate increased HDL-associated Lp-PLA 2 (HDL-Lp-PLA 2 ) activity and mass attributable to a preferential increase in Lp-PLA 2 associated with the HDL-3c subfraction. Conclusion-Ezetimibe, rosuvastatin, and fenofibrate reduce Lp-PLA 2 activity and mass associated with the atherogenic apoB-lipoproteins. Furthermore, fenofibrate improves the enzyme specific activity on apoB-lipoproteins and induces the HDL-Lp-PLA 2 . The clinical implications of these effects remain to be established. (Arterioscler Thromb Vasc Biol.
P latelet-activating factor (PAF) acetylhydrolase exhibits a Ca 2ϩ -independent phospholipase A 2 activity and degrades PAF and oxidized phospholipids by catalyzing the hydrolysis of the ester bond at the sn-2 position. 1 PAF-acetylhydrolase in plasma is complexed to lipoproteins 2 ; thus it is also referred as lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ). 3 Lp-PLA 2 is associated mainly with apolipoprotein B (apoB)containing lipoproteins and primarily with low-density lipoprotein (LDL), whereas a small proportion of circulating enzyme activity is also associated with high-density lipoprotein (HDL). 1, 2 ⌻he majority of the LDL-associated Lp-PLA 2 activity is bound to the atherogenic small-dense LDL (sdLDL) particles, 2, 4, 5 and we recently showed that the enzyme activity is a marker of sdLDL particles in plasma. 6 Lp-PLA 2 is principally produced by hematopoietic cells including monocytes-macrophages. 7, 8 Lp-PLA 2 has been identified in atherosclerotic plaques 9 ; however, its role in atherosclerosis is still under investigation. In this regard, it is suggested that this enzyme might have an antiinflammatory role because it degrades and inactivates proinflammatory PAF and oxidized phospholipids 10, 11 ; other studies showed that Lp-PLA 2 may have a proinflammatory and proatherogenic role 12 because it generates lysophosphatidylcholine (lysoPC) 3, 13 and bioactive oxidized fatty residues. 3 Data from large White population studies demonstrated an independent association between plasma Lp-PLA 2 with cardiovascular disease (CVD) risk. In this regard a recent metaanalysis showed that Lp-PLA 2 is significantly associated with CVD, and the risk estimate appears to be relatively unaffected by adjustment for conventional CVD risk factors. 14 In contrast to total plasma enzyme, which mainly represents the LDL-associated Lp-PLA 2 , several lines of evidence suggest that HDL-associated Lp-PLA 2 activity, although at low levels, contributes to the antiatherogenic effects of this lipoprotein. 1 However, the clinical value of HDL-associated Lp-PLA 2 as a potent inhibitor of the atherosclerotic process remains to be established.
Among the various agents used to treat patients with CVD, only drugs that affect lipid metabolism can significantly influence plasma Lp-PLA 2 . 15, 16 Thus several statins (atorvastatin, lovastatin, simvastatin, and fluvastatin) reduce the enzyme activity in plasma in parallel to a reduction in LDL-cholesterol levels. [17] [18] [19] [20] [21] In contrast, pravastatin increased plasma Lp-PLA 2 activity, 22 whereas other investigators suggested that pravastatin reduced plasma Lp-PLA 2 mass. 23 Fibrates reduce plasma Lp-PLA 2 activity but significantly increase the HDL-associated Lp-PLA 2 activity. 16, 24 These data suggest that there are significant differences on the effect of various hypolipidemic drugs on Lp-PLA 2 activity or mass in total plasma and in lipoprotein subspecies. To provide more insights into the effect of hypolipidemic drugs on plasma Lp-PLA 2 , we investigated the effect of 3 agents that exert their action through different mechanisms (rosuvastatin, ezetimibe, and fenofibrate) on Lp-PLA 2 activity and mass in total plasma and in lipoprotein subspecies in hyperlipidemic patients.
Materials and Methods

Patients
One hundred and fifty hyperlipidemic patients participated in the present study. According to their lipid levels, patients were divided into the following groups: (1) primary hypercholesterolemia (type IIA dyslipidemia group, nϭ50, who were administered rosuvastatin), (2) type IIA dyslipidemia (nϭ50, who were administered ezetimibe), and (3) primary hypertriglyceridemia (type IV dyslipidemia, nϭ50, who were given micronized fenofibrate). Details on patient selection criteria, patient characteristics, and treatment are provided in the Data Supplement, available online at http://atvb.ahajournals.org.
Biochemical Parameters
Lipoprotein subclass analysis was performed electrophoretically by use of high-resolution 3% polyacrylamide gel tubes and the Lipoprint LDL System (Quantimetrix). Subfractionation of plasma lipoproteins by was performed by isopycnic density gradient ultracentrifugation. Lp-PLA 2 activity was measured by the trichloroacetic acid (TCA) precipitation procedure with the use of [ 3 H]-PAF (100 mol/L final concentration) as a substrate. Lp-PLA 2 mass was determined by use of a dual monoclonal antibody immunoassay standardized to recombinant Lp-PLA 2 (PLAC test; diaDexus, Inc). Data are presented as meanϮSD, except for Lp(a), which was expressed as the median and range. Statistical analysis was performed using SPSS 13.0 softpack. Details on the methodology used and statistical analysis are provided in the Data Supplement, available online at http://atvb.ahajournals.org.
Results
Effect of Hypolipidemic Therapy on Serum Lipid Profile
As shown in supplemental Table I (available online at http://atvb.ahajournals.org), ezetimibe significantly decreased serum total cholesterol, LDL-cholesterol, non-HDL-cholesterol, and apoB levels. Furthermore, ezetimibe induced a slight but significant reduction in serum HDL-cholesterol levels whereas it did not affect apoA-I levels. Rosuvastatin significantly decreased serum triglycerides, total cholesterol, LDL-cholesterol, non-HDL-cholesterol, and apoB levels. The reduction in these serum lipid parameters was more profound compared with the ezetimibe group. Fenofibrate significantly decreased serum levels of triglycerides, total cholesterol, LDL-cholesterol, non-HDL-cholesterol, and apoB. Furthermore, fenofibrate induced a significant increase in the serum levels of HDL-cholesterol and apoA-I, a phenomenon not observed in the other 2 groups. Finally, no alterations in the baseline Lp(a) levels were induced by any lipid-lowering therapy (supplemental Table I ).
Effect of Hypolipidemic Therapy on Lipoprotein Subclasses
Type IV dyslipidemic patients had higher plasma levels of VLDL-cholesterol and lower levels of IDL-cholesterol and buoyant LDL-cholesterol at baseline compared with type IIA dyslipidemic patients of either the ezetimibe or the rosuvastatin group. Type IV dyslipidemic patients had significantly higher baseline levels of sdLDL-cholesterol and a higher proportion of sdLDL whereas the mean LDL size was lower compared with type IIA patients. Treatment with either ezetimibe or rosuvastatin significantly reduced the mass of all apoB-containing lipoprotein subclasses, with the exception of VLDL-cholesterol, which was not reduced by ezetimibe. However, neither drug affected sdLDL proportion and mean LDL size. Fenofibrate significantly reduced VLDL-cholesterol levels but it did not affect IDL-cholesterol or buoyant LDL-cholesterol levels. Finally, fenofibrate reduced sdLDLcholesterol levels (and therefore the proportion of sdLDL) and increased mean LDL size ( Table 1) .
Type IV dyslipidemic patients had lower levels of HDL-2 and HDL-3 subclasses at baseline compared with type IIA patients of either ezetimibe or rosuvastatin group. Ezetimibe significantly reduced the concentration of small HDL-3 subclass without affecting the concentrations of the large HDL-2 subclass. In contrast, rosuvastatin did not affect the mass of either HDL subclass. Finally, fenofibrate significantly increased the mass of both HDL subclasses (Table 1 ).
Plasma Lp-PLA 2 Activity and Mass
Ezetimibe significantly decreased total plasma and non-HDL-Lp-PLA 2 activity and mass (Table 2) ; however, it did not affect the enzyme specific activity or the Lp-PLA 2 activity to apoB ratio (in nmol/mg/min, 0.58Ϯ0.13 before versus 0.60Ϯ0.15 posttreatment) and the Lp-PLA 2 mass to apoB ratio (in ng/mg, 3.75Ϯ0.51 before versus 3.83Ϯ0.98 posttreatment). Rosuvastatin significantly reduced total plasma and non-HDL Lp-PLA 2 activity and mass; these reductions were more pronounced compared with those induced by ezetimibe ( Table 2 ). Like ezetimibe, rosuvastatin did not alter the enzyme specific activity or the ratios of Lp-PLA 2 activity or mass to apoB. Fenofibrate significantly reduced total plasma and non-HDL Lp-PLA 2 activity. Importantly, fenofibrate induced a significant increase in the total plasma and non-HDL enzyme specific activity ( Table 2) . Baseline and posttreatment corrrelations between non-HDL-Lp-PLA 2 activity and mass are shown in Figure 1 .
Ezetimibe induced a slight but significant reduction in HDL-Lp-PLA 2 activity and mass but it did not affect the enzyme specific activity or the HDL-Lp-PLA 2 activity to apoA-I ratio (in nmol/mg/min, 0.021Ϯ0.005 before versus 0.021Ϯ0.006 posttreatment) and the HDL-Lp-PLA 2 mass to apoA-I ratio (in ng/mg, 0.52Ϯ0.17 before versus 0.49Ϯ0.18 posttreatment). By contrast rosuvastatin did not affect either of the above parameters.
Importantly, fenofibrate increased HDL-Lp-PLA 2 activity and mass but it did not affect the enzyme specific activity ( Table 2 ). Furthermore, fenofibrate significantly increased the ratios of HDL-Lp-PLA 2 activity to apoA-I (in nmol/mg/min, 0.019Ϯ0.008 before versus 0.030Ϯ0.009 posttreatment, PϽ0.03) or HDL-Lp-PLA 2 mass to apoA-I (in ng/mg, 0.48Ϯ0.16 before versus 0.69Ϯ0.21 posttreatment PϽ0.03).
Lp-PLA 2 Activity and Mass on Lipoprotein Subfractions
We further investigated the effect of hypolipidemic drugs on the Lp-PLA 2 activity and mass associated with the apoB-and apoA-I-containing lipoprotein subspecies, isolated by density gradient ultracentrifugation. Among the apoB-containing lipoproteins, Lp-PLA 2 activity and mass were preferentially associated with the dense LDL-5 subfraction in all patient groups at baseline (Figure 2A and 2B) , a finding that is in accordance to our previous results. 6, 17, 24 Ezetimibe significantly reduced the enzyme activity and mass (expressed per mL of plasma) associated with all apoB-containing lipoprotein subfractions (Figure 2A and 2B) , whereas it did not affect the enzyme activity or mass when it was expressed per mg of protein (data not shown).
Rosuvastatin reduced the enzyme activity and mass (expressed per mL of plasma) associated with all apoBcontaining lipoprotein subfractions (Figure 2A and 2B) . Remarkably, it significantly reduced the enzyme activity and mass (expressed per mg of protein) in the dense LDL-5 subfraction (Lp-PLA 2 activity, nmol/mg/min: 38Ϯ13 at baseline versus 20Ϯ9 posttreatment, PϽ0.03; Lp-PLA 2 mass, ng/mg: 95Ϯ29 at baseline versus 50Ϯ18 posttreatment, PϽ0.03). Neither ezetimibe nor rosuvastatin affected the enzyme specific activity of each apoB lipoprotein subfraction ( Figure 2C ). It should be noted that the Lp-PLA 2 specific activity at baseline in apoB-containing lipoprotein subfractions ranges from 0.3 (LDL-5) to 2.3 nmol/ng/min (LDL-3) (Figure 2) whereas the non-HDL enzyme specific activity in the same patient groups is lower and ranges from 0.12 to 0.22 nmol/ng/min (Table 2) . However, when the enzyme specific activity in LDL-5 and LDL-3 was determined in the presence of human serum albumin or total plasma proteins (prepared as described in the methods section), it was reduced in a dose-dependent manner. Thus at an albumin or total plasma protein concentration of 6 g/dL a significant reduction of 50Ϯ8% in both subfractions for both treatments was observed, suggesting that plasma proteins, primarily albumin, significantly affect the enzyme activity a finding, which is in accordance with previously published results. 25 Thus the Lp-PLA 2 specific activity in LDL-5 in the presence of 6 g/dL albumin is 0.15Ϯ0.02 nmol/ng/min being similar to that of the non-HDL-Lp-PLA 2 , a finding consistent with the preferential association of the non-HDL enzyme with LDL-5. Fenofibrate significantly reduced the Lp-PLA 2 activity and mass associated with the VLDLϩIDL subfraction ( Figure 3A and 3B), whereas it did not affect the enzyme-specific activity of this subfraction ( Figure 3C ). Fenofibrate did not affect the activity, mass, or specific activity of the enzyme associated with large and intermediate LDL particles (LDL-1 to LDL-4); however, it significantly reduced the enzyme activity and mass associated with LDL-5 ( Figure 3A and 3B ). Furthermore, fenofibrate induced a significant increase in the specific activity of Lp-PLA 2 associated with this subfraction ( Figure 3C ).
Finally, it should be noted that no detectable amounts of Lp(a) were found in any lipoprotein subfraction at baseline or after treatment with any hypolipidemic drug. Thus it is unlikely that the alterations in the Lp-PLA 2 associated with LDL subfractions induced by hypolipidemic therapy are influenced by changes in the Lp(a) levels and in the Lp(a)associated Lp-PLA 2 .
Among the HDL subfractions, Lp-PLA 2 activity and mass in all patient groups at baseline were preferentially associated with HDL-3c, a finding which is in accordance with our previously published results. 6, 17, 24 Ezetimibe slightly, albeit significantly, reduced Lp-PLA 2 activity and mass associated with the HDL-3c subfraction, a phenomenon not observed after rosuvastatin administration. By contrast, fenofibrate significantly increased Lp-PLA 2 activity and mass associated with HDL-3c ( Figure 4A and 4B) . Neither drug influenced the activity or mass of Lp-PLA 2 associated with the other HDL subfractions. Finally, neither drug affected the enzyme specific activity on any HDL subfraction (in nmol/ng/min, 0.32Ϯ0.12 for HDL-2b, 0.24Ϯ0.10 for HDL-2a, 0.12Ϯ0.04 for HDL-3a, 0.07Ϯ0.02 for HDL-3b, and 0.04Ϯ0.01 for HDL-3c).
It should be emphasized that the mean value of enzyme specific activity in total HDL formed by mixing of equal volumes of all HDL subfractions (0.15 nmol/ng/min), is much lower compared with that of total LDL formed by mixing of equal volumes of the subfractions LDL-1 to LDL-5 (1.34 nmol/ng/min). Importantly, when both lipoproteins were dissociated by treatment with 0.1% Triton X-100, the Lp-PLA 2 specific activity on LDL was significantly reduced to 0.93 nmol/ng/min (PϽ0.03) because of the increase by 36% in the enzyme mass (from 23.8Ϯ4.2 to 32.4Ϯ5.1 ng/mg of total protein, PϽ0.03). Neither the enzyme activity in both lipoproteins nor the enzyme mass in HDL was significantly influenced by this treatment. These results show that the method used for the determination of Lp-PLA 2 mass may not detect all active enzyme in LDL, a phenomenon not observed for HDL.
Discussion
The present study compares for the first time the effect of 3 hypolipidemic drugs (ezetimibe, rosuvastatin, fenofibrate), which exert their action through different mechanisms, on plasma Lp-PLA 2 activity and mass. All drugs reduce Lp-PLA 2 activity and mass associated with the atherogenic apoB-containing lipoproteins. Furthermore, fenofibrate increases the specific activity of the enzyme associated with these lipoproteins and specifically that of the most atherogenic dense LDL-5 subfraction.
Fenofibrate reduces Lp-PLA 2 activity and mass associated with apoB-containing lipoproteins, an effect that could be mainly attributed to the preferential reduction of the enzyme associated with LDL-5 particles, 24 ie, those particles carrying the majority of LDL-associated enzyme. 2, 6 In accordance with our previously published results, 24 the present study shows that the above reduction is attributed to the fenofibrate action to decrease sdLDL and to increase large buoyant LDL particles, which have a higher clearance rate than sdLDL. 26 A contributory role to the reduction of Lp-PLA 2 by fenofibrate plays also the decrease in enzyme associated with the triglyceride-rich VLDLϩIDL subfraction (attributable to the drug-induced reduction in the plasma concentration of this subfraction). An important observation of the present study is that the non-HDL-Lp-PLA 2 specific activity is significantly increased by fenofibrate. According to our previous results, the specific activity of Lp-PLA 2 associated with large buoyant LDL is higher than that of either LDL-5 or VLDLϩIDL subfraction. 6 In this regard, the results of the present study show that the method used for the determination of Lp-PLA 2 mass may not detect all active enzyme in LDL, a phenomenon not observed for HDL, suggesting that structural differences among lipoprotein species may significantly influence the determination of enzyme mass, a hypothesis that needs further investigation. Based on the above observations, we may suggest that the increase in non-HDL-Lp-PLA 2 specific activity by fenofibrate is attributed to the drug-induced preferential reduction in the enzyme associated with LDL-5 and VLDLϩIDL subfractions. A contributory role in the above phenomenon may also play the fenofibrate-induced increase in the specific activity of Lp-PLA 2 associated with LDL-5.
In accordance with our previously published results, 24 fenofibrate treatment increases the HDL-Lp-PLA 2 activity. It also increases the HDL-Lp-PLA 2 mass, thus it does not affect the enzyme specific activity. This effect is attributable to the drug-induced increase in plasma levels of both HDL-2 and HDL-3 subspecies as well as to the preferential enrichment of the HDL-3c in Lp-PLA 2 . We had previously suggested that the latter phenomenon is attributed to enzyme transfer from triglyceride-rich apoB-containing lipoproteins to HDL during their enhanced lipolysis by lipoprotein lipase induced by fenofibrate. 24, 27 Although the role of the HDL-Lp-PLA 2 in humans has not been established yet, data from in vitro experiments as well as in vivo studies in animal models suggest that this enzyme may significantly contribute to the antiatherogenic effects of HDL (reviewed in 1 ). Consequently, the increase of HDL-Lp-PLA 2 induced by fenofibrate may represent an important antiatherogenic effect of this drug, a hypothesis that needs further investigation.
The present study further demonstrates that the administration of rosuvastatin in type IIA dyslipidemic patients significantly reduces Lp-PLA 2 activity and mass associated with apoB-containing lipoproteins. This reduction is the highest observed among all statins used in previous studies, 16 -23 and it could be primarily attributed to the druginduced reduction in the plasma concentration of all LDL subfractions and to the preferential reduction of Lp-PLA 2 associated with LDL-5. It has been suggested that simvastatin reduces LDL-associated Lp-PLA 2 not only through the receptor-mediated removal of LDL but also through a receptor-independent clearance of the lipid and enzyme contents of LDL. 20 This mechanism may explain our results on the preferential reduction in Lp-PLA 2 associated with LDL-5 (expressed per mg of protein) induced by rosuvastatin.
Ezetimibe is a drug that acts by inhibiting the absorption of cholesterol at the brush border of the intestinal wall. 28, 29 The present study shows for the first time that it reduces the plasma levels of Lp-PLA 2 mass and activity (although to a lesser extent compared with rosuvastatin and fenofibrate), by reducing the plasma concentration of all apoB-containing lipoprotein subfractions. Furthermore, ezetimibe induces a slight but significant decrease in the HDL-Lp-PLA 2 activity and mass. This follows the lowering effect of ezetimibe on plasma HDL-cholesterol levels a finding, which is not consistent in all studies 30 and may reflect the relatively high pretreatment levels of HDL-cholesterol in our population resulting in a regression to the mean effect. Because ezetimibe does not influence the ratio of enzyme activity or mass to apoA-I levels, we suggest that the reduction in HDL-3 plasma concentration may account for the ezetimibeinduced decrease in the HDL-Lp-PLA 2 . This is further supported by the finding that ezetimibe decreases the enzyme associated only with HDL-3c subfraction. It should be noted that all patients treated with ezetimibe were statin-intolerant, therefore the above results may not be representative of other groups given ezetimibe.
In addition to LDL and HDL, another carrier of Lp-PLA 2 in plasma is Lp(a). Interestingly, we 31 and others 32 have demonstrated that Lp(a) is enriched in Lp-PLA 2 compared with LDL. However, Lp(a) can influence the distribution of Lp-PLA 2 between LDL and HDL in plasma only when its plasma levels exceed 8 mg/dL. 31 Thus, it is unlikely that the Lp(a)-associated Lp-PLA 2 could influence the enzyme changes induced by hypolipidemic drugs, because the present results showed that no alterations in Lp(a) levels were induced by any lipid-lowering therapy and no patient exhibited a baseline or posttreatment Lp(a) levels above 8 mg/dL. Finally, no detectable amounts of Lp(a) were found in any lipoprotein subfraction at baseline or after treatment with any hypolipidemic drug.
Clinical studies have shown an independent association between plasma levels of Lp-PLA 2 mass or activity and CVD. 14 The present study further shows that the determination of Lp-PLA 2 mass, activity, and specific activity on individual lipoprotein subfractions may be pathophysiologically and clinically important. In this regard, we have previously shown that the preferential enzyme distribution on sdLDL particles compared with large buoyant apoBcontaining has as a consequence an increased production of lysoPC, the main metabolite of Lp-PLA 2 , during oxidation of this subfraction. 13 Several studies have supported the important role of lysoPC in atherogenesis, 33 and more recently it was shown that local coronary production of lysoPC is associated with endothelial dysfunction and early atherosclerosis. 34 Furthermore, the preferential association of Lp-PLA 2 with HDL-3 subfraction as compared with other apoA-Icontaining lipoproteins may contribute to the antiinflammatory and antioxidant effects of these particles. 1 Finally the Lp(a)-associated Lp-PLA 2 may play an important role in the metabolism of oxidized phospholipids in humans, in view of emerging data showing that oxidized phospholipids in plasma are preferentially sequestered on Lp(a). 35 Taking into account our previous results showing that the type of dyslipidemia and the underlying metabolic defect significantly influence the enzyme distribution among lipoprotein subspecies, 5, 17, 24 we suggest that the determination of enzyme parameters on specific lipoprotein subspecies may provide useful informa-tion on both pathophysiological and clinical basis, in addition to the valuable information provided from the measurement of Lp-PLA 2 mass and activity in total plasma.
A limitation of the present study could be the selection of patients who were allocated to different therapeutic agents according to the NCEP ATPIII goals that resulted in populations with different types of dyslipidemias. Thus it must be acknowledged that the different lipid abnormalities observed between Type IIA and Type IV patient groups may have contributed to the differential effect on the lipoproteinassociated Lp-PLA 2 levels of fenofibrate (administered in Type IV patients) compared with rosuvastatin or ezetimibe (given to Type IIA individuals).
In conclusion the present study demonstrates for the first time that fenofibrate, rosuvastatin, and ezetimibe (acting through different mechanisms) reduce Lp-PLA 2 activity and mass associated with the atherogenic apoB-containing lipoproteins, the rosuvastatin exhibiting the most potent effect. Additionally, fenofibrate increases the specific activity of the non-HDL-Lp-PLA 2 as well as the HDL-Lp-PLA 2 mass and activity. The clinical implications of these effects remain to be established.
